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PREFACE
Definition of Terms
ABT 199: molecule designed to selectively bind and inhibit Bcl-2, a critical regulator of
apoptosis. Bcl-2 is hypothesized to play a vital role as the final protein in the neuroprotective
pathway utilized by PNU-282987.
ACh: acetylcholine, a neurotransmitter utilized in the human body at all autonomic ganglia, at
many autonomically innervated organs, at the neuromuscular junction, and at many synapses
in the CNS. In the mammalian retina, acetylcholine is released from starburst amacrine cells and
acts on both nicotinic and muscarinic receptors on retinal ganglion cells.
Allosteric modulation: the modification of an enzyme or protein via the process of ligand
binding at an allosteric site (a site physically distinct from the protein’s active site) which
enhances or diminishes the action of substrate at the active binding site.
α7 nAChR: alpha-7 nicotinic acetylcholine receptor, located on retinal ganglion cells within the
mammalian retina and hypothesized to play a role in neuroprotection.
Excitotoxicity: neuronal cell death caused by overstimulation of receptors, specifically by the
amino acid neurotransmitter, glutamate. In the retina, diseases associated with excitotoxicity
include glaucoma, retinal ischemia, and diabetic retinopathy.
IOP: intraocular pressure, or pressure within the eye which is determined by the coupling of
production of aqueous humor from ciliary epithelium and drainage of aqueous humor through
the trabecular meshwork. Often this pressure is increased in a glaucomatous state.
LY 294002: a potent inhibitor of class I phosphoinositide 3-kinases, which signal through Akt to
hypothetically enhance the action of Bcl-2, an anti-apoptotic protein.
Neuroprotection: any therapeutic strategy aimed at the prevention or delay of
neurodegenerative processes.
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PAM: positive allosteric modulator, a ligand that binds an allosteric site of a protein or enzyme
to structurally modify and enhance the activity of an orthosteric (primary) agonist at the active
site.
PNU-120596: a novel positive allosteric modulator of the α7 nAChR which not only increases
the potency and maximal efficacy of agonists but also is the first to demonstrate modification of
neuronal activity in vivo.
PNU-282987: a potent, specific agonist of the α7 nAChR which is found on retinal ganglion cells
within the retina.
RGC: retinal ganglion cell, a type of neuron located on the inner surface of the retina which
receives visual information from photoreceptors. Retinal ganglion cells transmit vision-forming
information to the brain via their axons, which collectively form the optic nerve. Death of these
neurons is the hallmark pathologic feature of glaucoma.
SB 203580: an inhibitor of MAP kinase signaling, specifically of p38 MAP kinase which is
implicated in the excitotoxic pathway of retinal ganglion cells.
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ABSTRACT

Glaucoma is one of several neurodegenerative diseases of the central nervous system for which
a pharmacologic cure is yet to be discovered. In previous studies acetylcholine (ACh) has
provided neuroprotection for retinal ganglion cells (RGC) in the mammalian retina under
glaucomatous conditions (Wehrwein et al., 2004). More specifically, an α7 nicotinic ACh
receptor (nAChR) agonist has demonstrated neuroprotection for RGCs in both in vitro and in
vivo models of glaucoma (Iwamoto et al., 2014). In this study, this α7 nAChR agonist was
combined with a positive allosteric modulator (PAM) in dissociated adult porcine retinas to
evaluate its effect on isolated RGCs and identify a potential molecular signaling pathway of
neuroprotection.

Porcine retinas were dissociated using a two-step panning technique to isolate RGCs. Once
isolated, RGCs were cultured under various pharmacologic conditions and incubated for 3 days.
Pharmacologic conditions utilized throughout the course of this research included: agonist
alone, agonist with low, medium or high dose PAM, and PAM without agonist. In subsequent
experiments, enzyme inhibitors were applied thirty minutes prior to pharmacologic
intervention to evaluate effects of the drugs in the absence of specific proteins utilized in their
hypothesized cellular signaling pathway.

Retinal ganglion cells treated with the α7 nAChR agonist alone demonstrated a 28.0% (± 12.8%)
increase in cell survival over untreated control. This agonist in combination with medium or
high dose PAM resulted in increased cell survival at 43.0% (± 11.6%) and 52.0% (± 20.9%),
7

respectfully. However when the PAM was used as monotherapy, cell survival increased by only
3.2% (± 10.4%) over untreated control, supporting its hypothesized allosteric mechanism of
action. Enzyme inhibition results suggest that the α7 nAChR agonist utilizes the PI3 to Bcl-2
signaling pathway to produce this neuroprotective effect, and that the PAM works in an
allosteric manner through PI3 kinase to produce an enhanced effect. These studies provide
support for future research in analyzing the effects of an α7 nAChR agonist and PAM in in vivo
models of RGC death. Further understanding of these pharmacologic agents could provide
important information in the development of new therapeutic options for glaucoma and other
neurodegenerative diseases.
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CHAPTER 1
INTRODUCTION

Background
Glaucoma is a pathologic state in which a combination of increased intraocular pressure,
damage to the optic nerve, and death of retinal ganglion cells result in loss of vision and
ultimately, irreversible blindness. According to the World Health Organization’s 2012 statistics,
there are an estimated 285 million people in the world who are visually impaired, 39 million of
who are legally blind (WHO Media Centre, 2012). Of those, approximately 44.7 million people
are blind or visually impaired as a result of open-angle glaucoma, and this number is expected
to increase to 58.6 million people by 2020 (Jacobs, Trobe & Park, 2014). Consequently,
glaucoma is the second-leading cause of blindness in the world. In addition to this staggering
data, the American Academy of Ophthalmology estimates only 50% of the 3 million Americans
who suffer from open-angle glaucoma are aware that they have the condition (The Ophthalmic
News & Education Network, 2010). The insidious, chronic nature of open-angle glaucoma in
combination with the lack of curative treatment renders glaucoma a devastating medical
problem that needs to be addressed.
Treatment for glaucoma is limited. The American Academy of Ophthalmology lists
pharmacologic treatment, laser therapy, or incisional glaucoma surgery as treatment options,
with pharmacological eye drops being the most common (The Ophthalmic News & Education
Network, 2010). The problem with these options is that they all aim to treat the initial
12

pathology of increased intraocular pressure (IOP), but none addresses the underlying cause of
blindness- optic nerve damage and retinal ganglion cell (RGC) death. An increase in IOP results
when the outflow channels between the trabecular meshwork and the uveoscleral blood
vessels resist aqueous drainage from within the eye (American Glaucoma Society, 2013) or
when production of aqueous humor exceeds the capacity of the drainage system. When the
aqueous humor is unable to drain, either completely or at a rate sufficient for production, the
pressure within the eye rises. Elevated IOP is the number one risk factor for glaucoma, but it is
not widely accepted as the direct cause of blindness and is not present in all cases of glaucoma.
Increased IOP and RGC death have a cause and effect relationship. Most often, an increase in
IOP results in activation of pathways that are involved in apoptotic RGC death. However not all
cases of glaucoma present with IOP, and studies have shown lowering IOP does not ensure
prevention of RGC death (Sena et al., 2010). A specific class of glaucoma called normotensive
glaucoma presents with the same pathological findings as open-angle glaucoma in the absence
of elevated IOP (Munemasa & Kitaoka, 2013). All currently accepted therapies are targeted at
decreasing IOP since this is the only modifiable risk factor (American Glaucoma Society, 2013).
However, not all cases of glaucoma exhibit this risk factor and therapies focused on direct
protection of the optic nerve remain to be utilized.
There are numerous theories regarding the molecular mechanism behind RGC
degeneration associated with glaucoma. In addition to IOP elevation, the processes of oxidative
stress, autoimmune regulation, glial cell activation, endoplasmic reticulum stress, endothelin
receptor activation, neurotrophic factor deprivation, and excitotoxicity have all been implicated
in the degeneration of RGCs (Munemasa & Kitaoka, 2013; Kuehn et al., 2005). The process of
13

excitotoxicity, specifically excitotoxicity caused by the neurotransmitter glutamate, has been a
focus of extensive background study in this lab and others for decades. Glutamate is an
excitatory neurotransmitter that is released by presynaptic neurons in the mammalian nervous
system. Glutamate excitotoxicity is a pathological process involved in numerous degenerative
conditions throughout the central nervous system and within the retina (Munemasa & Kitaoka,
2013). Toxicity in the retina was first described in 1957 by Lucas and Newhouse who injected
glutamate subcutaneously in mice and observed severe destruction of the retinal ganglion cell
layer (Lucas & Newhouse, 1957). The term “excitotoxicity” was coined in 1969 to describe this
type of neuronal damage when similar effects were observed in neonatal mice (Olney, 1969).
In previous studies in both in vivo and ex vivo models, glutamate excitotoxicity via
increased concentrations of glutamate in the eye has shown to lead to a prolonged influx of
cations into RGCs, resulting in activation of apoptosis (Brandt et al., 2011; Asomugha et al.,
2010; Thompson et al., 2006). In the pig retina, glutamate has been demonstrated to bind to
both NMDA and non-NMDA glutamate receptors, activating a calcium-induced cascade that
ultimately results in RGC death through an apoptotic mechanism (Thompson et al., 2006).
Although the specific role of glutamate excitotoxicity in the overall pathology of glaucoma
remains unclear, drugs that target the prevention of this pathway have shown promise in
preventing RGC apoptosis (Danesh-Meyer, 2011).
With regards to glaucoma, neuroprotection is defined as an intervention administered
to prevent any one of the previously proposed mechanisms from causing optic nerve damage
or cell death (Danesh-Meyer, 2011). In recent years there have been numerous studies
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conducted to explore the development of novel neuroprotective strategies. According to a
review done by Prof. Helen Danesh-Meyer of the University of Auckland in 2011, 37 different
neuroprotective therapeutic agents were tested on the glaucoma model from 2010-2011. Of
these, a wide spectrum of RGC survival was attained through prevention of many of the
aforementioned target pathways. Previous studies from this lab and others have demonstrated
success in preventing RGC loss and axon degeneration through stimulation of nicotinic
acetylcholine receptors (nAChR) within the mammalian retina (Iwamoto et al., 2013; Brandt et
al., 2011; Thompson et al., 2006; Wehrwein et al., 2004).
Previous studies have demonstrated that neuroprotection results from the activation of
nicotinic acetylcholine receptors (nAChRs) with ACh or the receptor agonist, nicotine (Brandt et
al., 2011; Asomugha et al., 2010; Bader and Linn, 2007; Thompson et al., 2006; Wehrwein et al.,
2004). Further studies were then performed to investigate the intracellular mechanism of ACh
neuroprotection. Results of these studies suggest that ACh provides RGC protection by directly
stimulating an enzyme survival pathway, the PI3 kinase signaling pathway, and indirectly
inhibiting an excitotoxic pathway, the p38 MAP kinase pathway (Asomugha et al., 2010). It is
also hypothesized that this excitotoxic pathway which ACh inhibits is the same pathway that is
up-regulated in the presence of glutamate, a known cause of excitotoxic processes throughout
the CNS (Asomugha et al., 2010).
To further address the effectiveness of ACh neuroprotection, an in vivo study was
designed to test the role of ACh under physiologic conditions (Iwamoto et al., 2014).
Specifically, the α7 nAChR agonist PNU-282987 (Tocris Bioscience, 2006) was administered via
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eye drops to the intact eye of Long Evans rats. This compound was originally developed by
Pfizer but sold when learned to have toxic effects systemically. Use of this substance in the
retina remains a viable option as drugs administered in eye drop form have minimal systemic
absorption. This was specifically tested by Linn et al. in 2011 in an in vivo model; PNU-282987 in
eye drop form penetrates retinal tissue while trace amounts could be detected in blood plasma
systemically (Linn DM et al., 2011; Farmen et al., 2011). Further results of in vivo use of PNU282987 in eye drop form in the intact retina demonstrated prevention of RGC loss in a dosedependent manner. This in vivo study utilized rats with surgically modified elevations in IOP to
mimic glaucoma conditions. When glaucomatous rats were treated with low-dose agonist in
eye drop form for 30 days post-surgery there was no significant reduction in RGC loss. However,
with a medium dose of agonist, significant neuroprotection resulted with total cell numbers
approaching that of the control eye. With a high dose, the percentage of RGCs increased in the
experimental eye in comparison to the untreated control eye (Iwamoto et al., 2014).
Under normal conditions, neurons are not actively dividing cells. In humans the majority
of the neocortex is formed from stem cells before birth and neurogenesis ceases in adulthood.
However, the application of PNU-282987, a nAChR agonist, at a high concentration dosage
resulted in increased numbers of RGCs in the experimental eye as compared to the control eye
(Iwamoto et al., 2014). The medium dose resulted in similar numbers of RGCs under high IOP
conditions versus the control eye, suggesting successful use as a neuroprotective agent. Further
research is needed to investigate the cause of increased RGC counts at a higher dose of this
agonist. It is not clear if neurons are being induced to divide in a physiologic or pathologic
manner. It is possible that oncogenes are being activated resulting in neoplastic growth masked
16

as increased numbers of RGCs. It is equally possible that a normal growth factor pathway is
being activated resulting in controlled differentiation (Linn CL et al., 2011).
Expounding on these questions will be an important target of future research. If the
nAChR agonist is indeed stimulating an enzyme pathway utilized in RGC survival and inhibiting
the enzyme pathway utilized in excitotoxicity, these neuroprotective effects could be enhanced
with the addition of a positive allosteric modulator (PAM). A PAM is a compound that binds to a
site distinct from the agonist-binding site on the target receptor complex. This site on the
receptor complex is called the allosteric site, and its binding serves to indirectly amplify the
effect of an agonist at another discrete target (orthosteric) site on the same receptor complex.
Generally this is performed through induction of a conformational change in the orthosteric
binding site. In contrast to an orthosteric agonist, the allosteric modulator does not bind
directly to the active receptor site and thus does not produce a direct agonist effect of its own
(Schwartz & Holst, 2007). Instead, they enhance the sensitivity and/or efficacy of the receptor
during agonist activation (Hurst et al., 2005).
The prototypic example of a positive allosteric modulator is Diazepam (Valium).
Diazepam is a drug of the benzodiazepine class, which work by binding stereospecific
benzodiazepine receptors on the postsynaptic GABA neurons, located at several specific sites
throughout the CNS (Brunton, Chabner & Knollmann, 2011). Binding of Diazepam to a GABA
neuron enhances membrane permeability to chloride ions and thus induces hyperpolarization
and cell stabilization, but only in the presence of GABA. In the absence of natural GABA binding
Diazepam exerts no effect. It cannot activate receptors that are not being activated and
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therefore has a ceiling effect, allowing for a greater safety profile that other GABA agonists like
barbiturates. In this study the α7 nAChR PAM, PNU-120596, is hypothesized to work in this
same manner by enhancing the action of the α7 nAChR agonist, PNU-282987, at its target
receptor.
PNU-120596 is a novel positive allosteric modulator of the α7 nAChR which not only
increases the potency and maximal efficacy of agonist but also is the first to demonstrate
modification of neuronal activity in vivo (Hurst et al., 2005). Several PAMs of α7 nAChRs have
been previously described; these agents function to minimize the rapid desensitization of α7
nAChRs and maximize the peak evoked response that is characteristically induced by
orthosteric agonists (Gill et al., 2013). The PAM used in this study comprises an entirely new
class of PAM of the α7 nAChR as it the first drug of its kind to substantially modify the duration
of agonist evoked response (Hurst et al., 2005). If the agonist in question, PNU-282987,
provides neuroprotection to RGCs via binding to α7 nAChRs and up-regulating an enzymatic
survival pathway, an α7 nAChR PAM should amplify and prolong these effects to provide
enhanced protection from cell death. This study aims to address this hypothesis with the α7
nAChR positive allosteric modulator, PNU-120596 (Tocris Bioscience). Further research in this
field of study may have great implications in the search for a neuroprotective agent that can
prevent, or even possibly reverse, the loss of RGCs associated with glaucoma.
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Problem Statement
Glaucoma is one of the leading causes of blindness in the world. There has been a
significant amount of research dedicated to finding a cure, however at this point none has been
obtained. The drugs currently on the market do not target the true cause of vision loss, but
rather aim to slow the progression of severe neuron damage. With current IOP-lowering
medications, RGC death can be slowed but not fully stopped. A compound that acts directly on
the RGCs and their axons could be of benefit alone and in combination with current
medications. An analysis of the cellular effect of an α7 nAChR agonist and PAM could reveal
their effectiveness as a pharmacologic therapy to prevent the RGC loss associated with
glaucoma at a cellular level.
Aims of Study
The main objective of this study is to determine if the use of a positive allosteric
modulator can amplify the survival of retinal ganglion cells treated with the nAChR agonist
PNU-282987 under glaucomatous conditions. If amplified survival is achieved, further
investigation into the role of known signaling cascades utilized by various combinations of
agonist and PAM will be conducted.
Significance of Study
Evaluation of the result of isolated RGC treatment with PNU-282987 and a PAM may
reveal an increase in cell survival over the level which PNU-282987 can achieve as monotherapy. An amplification of cell survival would increase the clinical efficacy of this drug and
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promote advancing research in this field of study. The researchers in this study aim to promote
advancement in this field to develop a drug that can effectively prevent the death of RGCs
associated with vision loss in glaucoma.
Research Questions


Previously, in vitro glaucoma studies were conducted on RGCs that had their axons
severed (axotomy) during removal of the eye globe in the course of dissection. Thus,
one could hypothesize that the observed drop of RGCs in culture to a plateau level
(Wehrwein et al. 2004) reflects this damage. The addition of high levels of
glutamate in previous studies leads to an additional drop observed with this system.
Without the additional insult of glutamate, will an α7 nAChR agonist and PAM
increase RGC survival under axotomy conditions?
o Does the neuroprotection occur in a dose dependent manner?
o Is the neuroprotection seen with the combination of drugs significantly
higher than neuroprotection provided by agonist alone?
o At which concentration of α7 nAChR agonist and PAM does optimal
neuroprotection occur?



Previously, the α7 nAChR agonist has been proven to provide neuroprotection
through stimulation of the PI3 kinase pathway resulting in phosphorylation of Akt
and upregulation of Bcl-2 (Asomugha, Linn, & Linn, 2010). If the combination of α7
nAChR agonist and PAM also provide neuroprotection, is it a result of activation of
this same pathway?
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o If so, is the effect of the α7 nAChR agonist enhanced by the presence of the
PAM in an allosteric manner? Or, is an additional pathway activated?
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CHAPTER 2
LITERATURE REVIEW

Introduction
Glaucoma is a devastating, worldwide disease. In just the United States there are over 2
million estimated cases with 120,000 of those responsible for blindness. Unfortunately, only
half of those 2 million people are estimated to be aware of their condition (Glaucoma Research
Foundation, 2012). Angle-closure glaucoma is an acute condition associated with rapid onset of
severe pain, erythema and visual loss, and thus emergent surgery is employed as a therapeutic
intervention. In contrast, open angle glaucoma, the most common subtype of glaucoma, is an
insidious process that results in slow, progressive, and irreversible loss of the visual field
(Munemasa & Kitaoka, 2013). Early stages of open angle glaucoma may be asymptomatic,
allowing the disease to go unnoticed and progress to optic nerve damage. At this point no form
of treatment can restore lost vision (Sena et al., 2010) and thus screening for at-risk individuals
is vital in diagnosis. Still others will initiate treatment before this point of progression and still
experience optic nerve damage as a result of inadequate treatment options. Unlike most other
eye diseases, glaucoma is a lifelong neurodegenerative disorder that cannot be cured, only
treated (American Glaucoma Society, 2013).
The inadequacy of pharmacological therapy for glaucoma has landed it at the forefront
of numerous research studies in the recent past. According to a review done at the University
of Auckland in 2011, 37 different therapeutic agents were tested on the glaucoma model from
2010-2011 (Danesh-Meyer, 2011). The current medical strategy for treatment of glaucoma is
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medication or surgery to decrease intraocular pressure (IOP) - a strategy proven to slow
progression of the disease (The Ophthalmic News and Education Network, 2010). However,
axon deterioration and visual field loss have been observed in eyes with normal or decreased
IOP, suggesting that the disease process is at least partially independent of this variable
(Munemasa & Kitaoka, 2013). Despite these findings, reducing pressure in the eye remains the
only proven pharmacological therapy to slow the progression of glaucoma (American Glaucoma
Society, 2013). A true pharmacological cure for glaucoma is dependent upon the prevention of
RGC death as these are the cells responsible for transmitting visual impulses along their axons
to the visual processing center of the brain (Munemasa & Kitaoka, 2013).
Numerous strategies have been employed to prevent RGC death. These neuroprotective
strategies and their corresponding pharmacological agents have been tested on pre-clinical
animal models with varying success rates. One of the many challenges faced in development of
a successful pharmacotherapy is lack of knowledge of the underlying mechanism of
glaucomatous optic neuropathy (Danesh-Meyer, 2011). At this point in time considerable
research is still aimed at discovery of the true cause of optic neuropathy, if a single cause does
exist. Numerous methods of injury have been implicated including: oxidative stress,
autoimmune regulation, glial cell activation, endoplasmic reticulum stress, endothelin receptor
activation, neurotrophic factor deprivation, hypoperfusion of the optic nerve, and excitotoxicity
(Kuehn et al., 2005; Danesh-Meyer, 2011; Munemasa & Kitaoka, 2013). Drugs have been
successfully developed to target many of these injury processes with no specific therapy
showing significant success over the others. With widespread promise demonstrated in cellular
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and pre-clinical studies it is important to continue further research into narrowing the field of
study and translating it to a clinical setting for therapeutic use (Danesh-Meyer, 2011).
In 2010 a review was published by the Cochrane Collaboration detailing the state of
clinical advancement in neuroprotection as treatment for glaucoma in adults. The review was
performed to systematically examine the effectiveness of topical and oral neuroprotective
agents in prevention of RGC death in adults aged 30 years and older with open angle glaucoma.
Selection criteria was limited to randomized controlled trials with a minimum five year follow
up period in order to fully assess progression of visual field loss. Initial literature review
returned 1716 articles and 29 were chosen for primary inclusion. After further evaluation none
met the criteria for review (Sena et al., 2010). The results of this review reiterate the pressing
need for further clinical research in the field of glaucomatous neuroprotection. Although a
sufficient amount of cellular and animal research has been completed to date, very little has
been carried out to the clinical phase with results to provide evidence of clinical importance. Of
the 1716 articles initially returned, 15 potentially relevant trials were found with follow-up
periods ranging from two hours to two and a half years (Sena et al., 2010). This is a step in the
right direction although it is clear that further research needs to be directed into long-term
visual field preservation as glaucoma is a progressive and lifelong disease (Sena et al., 2010).
Comparative Literature
As stated previously, there are currently many theories and strategies in regards to RGC
and optic nerve injury and their appropriate treatment. One of those treatments investigated in
the Department of Ophthalmology at Harvard Medical School is Etanercept, marketed as
24

Enbrel, a widely used tumor necrosis factor-α (TNF-α) antagonist (Roh et al., 2012). TNF-α is a
pro-inflammatory cytokine that is secreted in response to infection and trauma and plays a role
in apoptosis of susceptible cells throughout the body (Roh et al., 2012). Prior to this study by
Roh et al., TNF-α was hypothesized to play a connecting role between increased IOP and RGC
death although its exact role was unclear. To investigate the role of TNF-α, Roh et al. used an in
vivo rat model with episcleral vein cauterization (EVC). This technique is used to elevate IOP
through cauterization and generation of scar tissue in the drainage system of the eye with
subsequent obstruction of outflow channels of aqueous humor resulting in rapid-onset
elevations in IOP. EVC was performed on the right eye to simulate the glaucoma-like condition
of elevated IOP, leaving the left eye untreated as a control. This is a widely-accepted and
commonly used mechanism for glaucoma model experimentation in animals (Danesh-Meyer,
2011). The TNF-α inhibitor was injected intraperitoneally and several parameters were
measured post-sacrifice (Roh et al., 2012).
Results from this study were suggestive of further use of Etanercept as a
neuroprotective agent for glaucoma. Eyes in rats subject to EVC demonstrated increased IOP
with a subsequent dramatic increase in retinal TNF-α levels, axonal degeneration, and a 38%
loss of RGCs (Roh et al., 2012). Eyes subject to EVC with Etanercept treatment also
demonstrated reduced TNF-α levels and axon degeneration as well as near-control levels of
RGCs. This study also determined that microglia cells activated by increased IOP are the source
of TNF-α in the retina and therefore provide the foundation for activation of RGC apoptosis.
Confirming both an increased level of TNF-α and a source for its production clarifies its role in
RGC loss (Roh et al., 2012). The results of this study are significant because they identified both
25

a cause and treatment of RGC loss in a glaucomatous state, charting a path for future research
into TNF-α antagonists as a treatment strategy for glaucoma.
Another theory in RGC degeneration is apoptosis as a result of hydrostatic pressureinduced oxidative stress on the retina. To further evaluate this theory, researchers at Shandong
University of Traditional Chinese Medicine studied the effects of alpha-lipoic acid (ALA), an
agent proven to provide protection against neurodegenerative disorders in humans and
experimental animals (Liu et al., 2012). The aim of study was to determine if ALA also produced
the same neuroprotective effects in the retina under glaucoma-like conditions. The study was
performed on an in-vitro model of cultured RGCs to determine if ALA provides the same
neuroprotective effect for RGCs as it has proven to provide for neurons in other neurologic
disorders related to oxidative stress such as Alzheimer’s disease, diabetic peripheral
neuropathy, subarachnoid hemorrhage, and traumatic brain and spinal cord injury (Liu et al.,
2012). The in-vitro model is useful for glaucoma because it facilitates assessment of molecular
changes and enzyme regulation of RGCs independent of environmental factors (Liu et al., 2012).
Liu et al. first isolated RGCs, followed by pretreatment with varying concentrations of
ALA (50 µM-200 µM). Pretreated and non-pretreated experimental cells were exposed to six
hours of hydrostatic pressure (50 mmHg) while pretreated and non-pretreated control cells
remained in a normal pressure environment. Results revealed cells that were subject to high
pressure without ALA pre-treatment experienced increases in apoptosis and intracellular
reactive oxygen species (ROS) production in comparison to non-pretreated control cells in a
normal pressure environment. In contrast, cells pretreated with ALA experienced significant
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reduction in ROS production and prevention of apoptosis through the mRNA expression of
manganese superoxide dismutase (MnSOD), an antioxidant enzyme (Liu et al., 2012). MnSOD
functions to counteract the injury inflicted by hydrostatic pressure through deactivation of ROS.
Researchers concluded that pre-treatment with ALA significantly increased the expression of
MnSOD leading to reduced production of ROS, resulting in inhibition of hydrostatic pressureinduced RGC degeneration in a dose-dependent manner. Through its antioxidant activity, ALA
supplementation has potential as a neuroprotective agent in glaucoma therapy. In addition,
ALA has already been used for years in the treatment of diabetic peripheral neuropathy and has
an established safety profile (Liu et al., 2012). Therefore, these results dictate further studies
directed towards the therapeutic value of ALA for glaucoma in a clinical setting.
Another recent theory suggests a correlation between glaucoma and Alzheimer’s
disease, as both involve neuronal loss through an apoptotic process. To further assess this
correlation, a team of Canadian researchers from universities in Quebec and Nova Scotia
worked together to study the effectiveness of the Alzheimer’s drug Galantamine as a
neuroprotective agent for RGCs (Almasieh et al., 2010). Galantamine is an acetylcholinesterase
(AChE) inhibitor and allosteric ligand of nAChRs that is used for symptomatic treatment of
Alzheimer’s. Through inhibition of AChE, the drug prevents breakdown of ACh and allows ACh
levels in the retina to increase and supposedly counteract the functional loss of cholinergic cells
due to disease process. Increased levels of ACh have proven to provide neuroprotection
through increased stimulation of AChRs in vitro. The mechanisms of neuroprotection in vivo
remain poorly defined, but results have proven that Galantamine increases survival of
hippocampal neurons and dopaminergic neurons in the treatment of Alzheimer’s. To determine
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if its neuroprotective effects translate to the treatment of glaucoma, an in vivo rat model was
used. Rats were subjected to elevated IOP through limbal vein obliteration via hypertonic saline
injection to mimic the effects of glaucoma. Treatment with Galantamine produced significant
neuroprotection for RGCs under these conditions (Almasieh et al., 2010).
Researchers next evaluated the functional effect of Galantamine on RGCs through
measurement of visual evoked potentials (VEP) after flash stimulation (Almasieh et al., 2010).
VEPs are evaluated by a recording electrode placed on the visual cortex which receives
predominantly RGC input, and therefore serve as a functional assay to determine if RGCs that
demonstrate structural protection also demonstrate functional protection. Initial results
revealed that both phosphate buffered saline (PBS)-treated and Galantamine-treated eyes
showed complete obliteration of VEPs five weeks post-EVC, despite a structural protection rate
of 70% of RGCs with Galantamine treatment. Researchers hypothesized that visual impairment
was mediated by sustained elevations in IOP and tested their hypothesis with a combination
therapy of Galantamine and Timolol, a topical β-adrenergic receptor blocker commonly used in
glaucoma therapy to decrease IOP. This combination therapy restored 47% of the VEP response
in Galantamine/Timolol treated eyes compared to a 0% response in PBS/Timolol treated eyes.
Lastly, researchers determined the mechanism of action of Galantamine through selective
pharmacological blockade of the two hypothesized pathways, nAChRs or muscarinic AChRs
(mAChRs). Galantamine provides neuroprotection in Alzheimer’s treatment through activation
of nAChRs, however results proved neuroprotection of RGCs was mediated through mAChRs
(Almasieh et al., 2010).
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This study produced important findings in the search for an effective pharmacological
therapy for glaucoma. First, Galantamine proved to be an effective pharmacological therapy in
the protection of RGCs in an in vivo model of glaucoma. Second, functional deficits seen in
glaucoma were markedly improved by a combination therapy of Galantamine and a βadrenergic receptor blocker. This supports further research into the use of novel
neuroprotective drugs in combination with currently used IOP-lowering drugs for long term
functional RGC protection and subsequent visual field preservation. Finally, Galantamine’s
effect was modulated by mAChRs, suggesting further research into their use as a therapeutic
target for prevention of RGC death and visual loss associated with glaucoma (Almasieh et al.,
2010).
Summary and Implications for Study
For the past decade, research has been conducted in this lab with the purpose of
determining the cause and prevention of RGC degeneration associated with glaucoma. Studies
have been directed at the prevention of neuronal degeneration as a result of glutamateinduced excitotoxicity, one of the major theories behind glaucomatous optic neuropathy, as
well as other implicated degeneration models. Previous studies have identified an excess of
glutamate in the vitreous humor of eyes affected by glaucoma, and that excess glutamate has
been proven to lead to a prolonged influx of nonspecific cations that activate pathways of
apoptosis within RGCs (Dryer et al., 1996). In a previous study, glutamate excitotoxicity was
tested on an in vitro model of isolated pig RGCs exposed to 500μM L-glutamate for various time
periods. By day 3, cells exposed to chronic glutamate had a mean 58% survival rate as
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compared to untreated isolated cells, suggesting glutamate had an excitotoxic effect on 42% of
isolated RGCs after a 72 hour period (Wehrwein et al., 2004). Further research determined this
excitotoxic effect was mediated through activation of both NMDA and non-NMDA glutamate
receptors (Wehrwein et al., 2004).
Next, a neuroprotective strategy was developed to prevent neuron degeneration
associated with glutamate excitotoxicity. As stated in the previous study, nAChRs are
considered to play a role in neuroprotection of hippocampal and cortical neurons in Alzheimer’s
therapy, although the exact mechanism of neuroprotection is unclear. Agonists of nAChRs,
acetylcholine (ACh) and nicotine, were tested for neuroprotective effectiveness on glutamateinduced excitotoxicity in the retina. Results showed increased RGC survival as a result of
pretreatment with ACh or nicotine before chronic glutamate exposure. Further
experimentation in combination with previous evidence suggested the neuroprotective effect
of the nAChR agonist was mediated through α7 nAChRs (Wehrwein et al., 2004). These findings
have since been supported with further research and expanded to include a potential
additional role of α4 nAChRs (Thompson et al., 2006).
Subsequent research was aimed at determining the mechanism of correlation between
nAChRs and neuroprotection. Two signaling pathways were hypothesized to be involved: p38
MAP kinase and PI3 kinase (Asomugha et al., 2010). The p38 MAP kinase pathway is associated
with inflammation and apoptosis. On the other hand, PI3 kinase is involved in a pathway that
induces activation of two other proteins that are actively involved in cell survival processes.
ELISA studies were performed on cultured pig RGCs and results revealed that glutamate
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excitotoxicity is mediated through the p38 MAP kinase signaling pathway while ACh
neuroprotection is mediated through stimulation of the PI3 kinase pathway and inhibition of
the p38 MAP kinase pathway (Asomugha et al., 2010). Further research revealed that the PI3
kinase survival pathway is activated by calcium permeation through nAChR channels activated
by an ACh agonist. Therefore, calcium is the trigger linking activation of nAChRs to activation of
neuroprotection (Brandt et al., 2012).
The next step was to evaluate an in vivo model to determine if ACh had a
neuroprotective effect under physiological conditions. A rat model was used and rats were
subject to limbal vein obliteration via hypertonic saline injection (Iwamoto et al., 2014) as was
used by Almasieh et al. in the galantamine study described previously. Injection of a hypertonic
solution leads to scarring of vessel lumen, decreasing diameter and increasing resistance to outflow. This technique is similar to the EVC technique described in previous studies as the
outcome of both procedures is resistance to aqueous humor drainage and ensuing elevation of
IOP mimicking glaucoma. EVC is rapid process with cauterization resulting in complete
obliteration; this in contrast to limbal vein occlusion which is a much more gradual process
taking up to a month for scarring to obliterate the venous lumen. Using the limbal vein
occlusion procedure, an α7 nAChR agonist, PNU-282987, was applied in eye drop form for 30
days post-procedure to 3 different dosing groups. Results revealed that rats treated with lowdose agonist for 30 days post-surgery experienced no significant reduction in RGC loss.
However, with a medium dose of agonist significant neuroprotection resulted, and with a high
dose the percentage of RGCs increased in comparison to the untreated control eye (Iwamoto et

31

al., 2014). These results support the use of a nAChR agonist for RGC neuroprotection and raise
the ensuing question of the mechanism of increased RGC counts in the high dose agonist group.
This study aims to further elucidate the mechanism of nAChR agonist neuroprotection in
the absence of additional elevated glutamate insult, as well as to examine the effectiveness of
the nAChR agonist in combination with a positive allosteric modulator (PAM). A PAM is a ligand
that binds an allosteric site distinct from the agonist-recognition site on its target receptor. It
has no agonistic activity when applied alone, but enhances the activity of agonist-evoked
responses when co-applied with an orthosteric agonist (Gill et al., 2013). In the setting of this
study, the application of a specific PAM of the α7 nAChR, PNU-120596, in combination with the
α7 nAChR agonist PNU-282987 should theoretically potentiate an increased neuroprotective
response. To test this hypothesis an in vitro model of isolated porcine RGCs will be used. The
same enzyme pathways implicated in previous study, p38 MAP kinase and PI3 kinase, will be
analyzed in the setting of both a nAChR agonist and PAM.
As previously stated, the p38 MAP kinase pathway is associated with inflammation and
apoptosis while the PI3 kinase pathway is involved in cell survival processes (Asomugha et al.,
2011). ELISA studies provided evidence to support glutamate’s role in excitotoxic cell death
through the p38 MAP kinase pathway that ultimately decreases levels of Bcl-2, an antiapoptotic regulator protein. Studies also provide evidence of the PI3 kinase pathway in
phosphorylation of Akt, which ultimately leads to increased expression of Bcl-2 (Asomugha et
al., 2011). If a nAChR agonist and PAM indeed provide neuroprotection by these enzyme
pathways, the neuroprotection would be eliminated in the presence of a Bcl-2 inhibitor. This
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concept will be the one of the main focuses of this study. Further elucidation of the role of
nAChR agonists, specifically in the presence of a PAM, will be beneficial in the search for novel
pharmacotherapeutic strategies for glaucoma.
Throughout the course of this study several hypotheses are tested, and these can be
summarized into five major parameters. First, in the absence of an elevated glutamate insult
the presence of an α7 nAChR agonist will increase RGC survival over control levels after three
days in culture. Second, RGC survival will be enhanced in the presence of an α7 nAChR PAM in
combination with the aforementioned agonist. Third, the increased RGC survival mediated by
PI3 kinase will be completely or nearly completely inhibited by a specific PI3 kinase inhibitor, LY
294002, in the presence of agonist alone or in combination with a PAM. Forth, the increased
cell survival expected via blockade of the cell death pathway, p38 MAP kinase, will be more
than observed for PI3 kinase inhibition. Fifth, Bcl-2 serves as the final target protein for the
increased survival mediated by PI3 kinase, thus inhibition of this protein will result in inhibition
of the cell survival mediated by PI3 kinase. Determination of the mechanism of cell survival
through evaluation of these pathways is crucial in understanding the pathway to and facilitating
the development of a clinically effective neuroprotective treatment for glaucoma.
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CHAPTER 3
METHODOLOGY

RGC Isolation Procedure
The study was performed using an in vitro preparation of isolated RGCs from adult
porcine eyes. The eyes were obtained from a local slaughterhouse (DeVries Meats,
Coopersville, MI) and kept on ice during transfer to the Cook-DeVos Center for Health Sciences
at Grand Valley State University. Severance of the optic nerve occurs upon removal of the eye
from its anatomic location in the orbit, therefore this mechanism of injury was employed even
before attaining eyes for dissection. Upon arrival the retina was dissected away from the
choroid and sclera posteriorly. Four retinas were then prepared for further dissociation using a
two-step panning process previously described by Wehrwein et al. (2004), Thompson et al.
(2006) and Asomugha et al. (2011). The panning process is schematically displayed in Figure 1.
To begin, isolated retinas were placed into a solution of CO₂-independent media (Gibco)
enriched with 4 mM glutamine, 5% fetal bovine serum (FBS), 5% antibiotic/antimycotic (Gibco)
and 4 mM HEPES. The retinas were each cut into eight pieces and enzymatically dissociated
with papain (27 u/mg) activated with cysteine for 20 minutes at 37°C. After 20 minutes the
enzymatic dissociation was inactivated with the addition of fresh CO₂-independent media and 1
mg/ml DNase to break up free DNA released from damaged cells. Physical dissociation by
titration and centrifugation for 2 minutes at 2000 rpm completed the retinal dissociation
process.
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The enzymatically and physically dissociated retinas were then transferred onto Petri
dishes pretreated with goat anti-rabbit IgG antibody (Jackson ImmunoResearch; 0.5 mg in 48 ml
of 20 mM Tris buffer). Petri dishes were prepared 24 hours prior by application of IgG antibody
evenly dispersed over the surface of four large (150 x 15 mm) Petri dishes, which were then
kept at 4°C overnight. On the day of experimentation, IgG-treated Petri dishes were washed
with three rinses of PBS and one rinse of PBS with 0.2% BSA. After 60 minutes of incubation
with PBS with 0.2% BSA this rinse was removed and dissociated retinas were applied.
Dissociated retinas were incubated on IgG-coated plates for 1 hour at 37° C to bind nonspecific
cellular content such as vascular tissue within the dissociated retina. This completed the first
step in the panning procedure.
After incubation for one hour, media containing unbound RGCs was removed from IgGcoated plates and transferred to Petri dishes pretreated with goat anti-mouse IgM (Jackson
ImmunoResearch; 0.3 mg in 48 ml of 20 mM Tris buffer) and mouse anti-rat Thy 1.1 antibody
(BD Biosciences; 10 µg in 10 ml PBS containing zero calcium and zero magnesium). These plates
were prepared in a similar manner as described previously with application of IgM antibody to
twelve small (60 x 15 mm) Petri dishes 24 hours prior to experimentation. On the day of
experimentation Ig-M coated plates were further prepared by removing excess IgM and
applying Thy 1.1 antibody (0.165 µg in 48 ml of 20 mM Tris buffer). Thy 1.1 antibody is used
because Thy 1.1 antigen is a RGC-specific marker in the retina (Asomugha et al., 2011). After
incubation for 60 minutes at 37° C, excess Thy 1.1 was removed and dishes were washed with
three rinses of PBS and one rinse of PBS with 0.2% BSA. After an additional 60 minutes of
incubation at 37° C the final rinse was removed and dishes were ready for tissue. The dishes
35

were incubated with remaining retina contents for 1 hour at 37°C; after this period RGCs were
bound to Thy 1.1 on the dishes and the supernatant containing unbound cells was then
removed and discarded. This completed the second and final step in the panning procedure as
the RGCs were bound to plates treated with Thy 1.1 antibody and therefore isolated from all
other retinal tissue. Fresh CO₂-independent media containing glutamate, FBS,
antibiotic/antimycotic, and HEPES was further enriched with nerve growth factor (0.3 µg/ml),
transferrin (1 µg/ml), and insulin (6 µg/ml) and added to the dishes to nourish isolated RGCs.
This isolation process has been thoroughly established and studied by Wehrwein et al.
who demonstrated that RGCs isolated in this nature, subject only to injury via optic nerve
severance, die off in a predicable manner over time. In enriched CO₂-independent media,
survival of RGCs with severed axons gradually decreases from 100% to a plateau at 61% survival
over the first 7 days in culture (Wehrwein et al., 2004). This model allows for evaluation of RGC
survival in the absence of the additional variable of added insult, much in the manner that an in
vivo study would employ.
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(4) IgG coated
plates
+
dissociated retinas
in media
Media
containing
unbound retina
content (RGCs)
(12) IgM+Thy 1.1
coated plates
+
remaining retina
content with RGCs
Excess media
and unbound
retina content

(3) Plate A
Control

(3) Plate C
Experimental
variable 2

(3) Plate B
Experimental
variable 1

Waste

(3) Plate D
Experimental
variable 3

Figure 1. Schematic of panning and RGC isolation protocol. IgM plates contain Thy 1.1 antibody
which binds Thy 1.1 antigen that is specific for retinal ganglion cells. RGCs remain bound to the
twelve IgM plates while all other retinal content is removed and discarded. Fresh media is
applied to each of the twelve plates in preparation for pharmacologic treatment. Plates A are
left untreated as control while Plates B, C & D receive pharmacologic treatment.
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Experimental Design
Before final incubation the isolated RGCs were treated with an α7 nAChR agonist, PNU282987 (Tocris, 10 µM in PBS), and varying doses of an α7 nAChR PAM, PNU-120596 (Tocris, 10
µM in PBS) to evaluate their effectiveness as neuroprotective agents for RGCs. Dosage of
agonist sufficient for neuroprotection was a subject of previous study by Bader and Linn, 2007,
therefore an effective dose of 100 nM agonist was utilized throughout this experiment. Five
experimental conditions were performed throughout the course of this study. Conditions 1 & 2
involved agonist and differing doses of PAM. Condition 1 tested the effect of increasing doses
of PAM and agonist while Condition 2 tested extreme doses of PAM to further evaluate its role
in neuroprotection. Because a PAM is an allosteric ligand it is proposed to have no effect when
working alone; this hypothesis is tested in treatment group D of Condition 2.
Conditions 3, 4 & 5 involved pre-treatment with enzyme pathway inhibitors prior to
application of agonist and PAM. The enzyme pathway inhibitors served to evaluate the
involvement of potential cell signaling cascades implicated in the aforementioned excitotoxic
and neuroprotective pathways. By pre-treating with one inhibitor per experiment, a single
enzyme or protein’s effect can be evaluated. Two enzymes and one protein were evaluated
throughout the course of this study. PI3 kinase, p38 MAP kinase, and Bcl-2 were inhibited in
Conditions 3, 4 & 5, respectively. A schematic of proposed enzyme pathway involvement in RGC
neuroprotection is provided in Figure 2. All five experimental conditions were completed with a
control variable (A) and three experimental variables (B, C & D); three dishes were created for
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each variable totaling 12 dishes in each experiment. The five experimental conditions are
further described in Table 1.

Figure 2. The proposed mechanism of neuroprotection of RGCs is illustrated on the right side of
diagram. PNU-282987 has been shown to utilize a binding site on nAChR to initiate an influx of
Na⁺ and Ca²⁺ and activate PI3 kinase. Ultimately, PI3 kinase activation promotes Bcl-2, an antiapoptotic protein. The PAM binds to an allosteric transmembrane site on the nAChR and is
proposed to act in an allosteric manner by increasing the influx of Na⁺ and Ca²⁺ in the presence
of PNU-282987 binding. If this is the true mechanism of action the PAM would have no activity
in the absence of PNU agonist. It is also possible that the PAM works through a different
unidentified pathway; this hypothesis is tested in Condition 2. The left side of the diagram
illustrates a proposed mechanism of excitotoxicity. Through activation of p38 MAP kinase, the
excitotoxic pathway inhibits Bcl-2 and thus promotes apoptosis. Activation of the PI3 kinase
pathway has inhibitory effects on this action of p38 MAP kinase.

39

Pharmacological Treatment
Doses used in all five conditions can be found in table format in Table 1. Doses of PNU282987 agonist sufficient for use as a neuroprotective agent were previously studied by Bader
and Linn, 2007, and employed in this study. In Condition 1 (n=9) the following pharmacologic
doses were used: A) cells were left untreated as a control, B) cells were treated with 100 nM
agonist, C) cells were treated with 100 nM agonist and 50 nM PAM, and D) cells were treated
with 100 nM agonist and 100 nM PAM. In Condition 2 (n=6) the following pharmacologic doses
were used: A) cells were left untreated as a control, B) cells were treated with 100 nM agonist,
C) cells were treated with 100 nM agonist and 20 nM PAM, and D) cells were treated with 100
nM PAM alone. In Condition 3 plates B, C & D were pre-treated with 10 nM LY 294002 to inhibit
PI3 kinase. After 30 minutes the following pharmacologic doses were used: A) cells were left
untreated as a control, B) cells were treated with 100 nM agonist, C) cells were treated with
100 nM agonist and 50 nM PAM, and D) cells were treated with 100 nM agonist and 100 nM
PAM. Conditions 4 & 5 were performed in an identical manner to Condition 3 but a different
enzyme inhibitor was used for pre-treatment in each. Condition 4 utilized treatment with 10
nM SB 203580 to inhibit p38 MAP kinase. Condition 5 utilized treatment with 10 nM ABT 199 to
inhibit Bcl-2. After application of inhibitor and/or drugs, cells were incubated at 37°C for three
days. An illustration of the enzyme inhibitor experiments, Conditions 3-5, is found in Figure 3.
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Experimental
Condition
Condition 1

A

B

Control

100 nM agonist

Condition 2

Control

100 nM agonist

Condition 3

Control

10 nM LY 294002
100 nM agonist

Condition 4

Control

10 nM SB 203580
100 nM agonist

Condition 5

Control

10 nM ABT 199
100 nM agonist

C
100 nM agonist
50 nM PAM
100 nM agonist
20 nM PAM
10 nM LY 294002
100 nM agonist
50 nM PAM
10 nM SB 203580
100 nM agonist
50 nM PAM
10 nM ABT 199
100 nM agonist
50 nM PAM

D
100 nM agonist
100 nM PAM
100 nM PAM
10 nM LY 294002
100 nM agonist
100 nM PAM
10 nM SB 203580
100 nM agonist
100 nM PAM
10 nM ABT 199
100 nM agonist
100 nM PAM

Table 1. Pharmacologic treatment as classified by experimental condition.

Suppression of
apoptosis
Figure 3. Demonstration of enzyme inhibitor experiment mechanism of action. In Condition 3,
LY 294002 is used to inhibit PI3 kinase, which is proposed to up-regulate the anti-apoptotic
protein, Bcl-2. In Condition 4, SB 203580 is used to inhibit p38 MAP kinase, which is proposed to
inhibit Bcl-2. In Condition 5, ABT 199 is used to inhibit Bcl-2 itself.

41

Equipment and Instruments
After a three day incubation period, pharmacologically treated and untreated RGCs
were labeled with 2 µM of membrane-permeable calcein, a fluorescent dye, for visualization
with fluorescence microscopy. Cells treated with calcein were incubated at 37°C for 30 minutes
to fluorescently label viable cells (Asomugha et al., 2011). Microscopy was performed with a
Nikon Diaphot epifluorescent research microscope illuminated by a 100-W mercury arc lamp
with an excitation filter FITC 460-490, dichroic mirror DM 580 and barrier filter BA 590. Images
were captured using a Hamamatsu XC-77 CCD camera and QCapture Pro 7 imaging system from
Image Analysis, Inc. To quantify cell density, four pictures of fluorescent cells were captured at
a consistent magnification from a predetermined location (12, 3, 6 and 9 o’clock positions) on
each dish. The number of cells in each of these four pictures was counted and averaged to
obtain a total representative of cell survival on each dish.
Data Analysis
The number of viable cells in each image was counted using Image-Pro software from
Media Cybernetics, Inc. An average was calculated for the four images captured for each dish,
and this average value was obtained for each of the 12 dishes in each experiment. Although all
RGCs were originally isolated under the same conditions, there is some variation in cell death
between experiments due to aspects of the dissociation process such as titration, variation in
time between eye removals and culture, etc. (Asomugha et al., 2011). Comparison of
experimental cell survival to untreated control survival within the same experiment eliminated
this variation between experiments. Data was organized such that randomized complete design
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with subsampling could be performed (Hinklemann & Kempthorne, 1994). Statistical analysis
was implemented on non-normalized data using two-way analysis of variance (ANOVA) with
interaction between plate and treatment. A P-value of less than 0.05 was considered
statistically significant for all tests.
Results of this study are limited to an evaluation of RGCs in isolation and extrapolation
to an in vivo system should be used with caution. However, this allows for true evaluation of
the effectiveness of pharmacological therapy and involvement of targeted enzyme pathways in
the absence of confounding variables. There are also numerous steps throughout the
dissociation process that leave room for human error in procedure. Nonetheless, consistent
results utilizing this technique have been published in several peer-reviewed journals. In
addition, only specific enzyme pathways were targeted for study. Involvement of other enzyme
signaling pathways were neither detected nor analyzed.
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CHAPTER 4
RESULTS

Cell Survival in Response to Pharmacotherapy
Experimental Conditions 1 & 2 investigated the effects of varying doses of α7 nAChR
agonist and PAM in an in vitro model of glaucoma using isolated RGCs. A membranepermeable fluorescent dye, calcein, was taken up by viable cells and results viewed under
fluorescence microcopy. An example of the results obtained following this procedure is shown
in Figure 4. Statistical analysis was used to evaluate significant differences in cell survival
between variables A, B, C & D within each experiment. Condition 1 (n=9) compared viable cells
in control plates to those in plates with agonist alone (B), agonist and low-dose PAM (C), and
agonist and high-dose PAM (D). Control plates (A) contained a significantly lower amount of
viable cells than did all other pharmacologically-treated plates in Condition 1 (p<0.0001). The
difference among plates (1, 2 & 3) within each treatment group (A, B, C & D) was not
statistically significant (p=0.8069) and there was no interaction between plate and treatment
(p=0.1562). This is a testament to the precision of experimental results and is true for all five
experimental conditions as none produced a p-value for interaction less than the accepted
value of 0.05.
Figure 4 demonstrates images taken from treatment groups A, B, C & D of a Condition 1
experiment. Pictures demonstrate viable RGCs stained with calcein three days after isolation.
There is a noticeable and direct increase in viable cells sequentially from A to D that
corresponds with increasing doses of pharmacotherapy. The least squares means for viable
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cells of Condition 1 are as follows: treatment A = 34.73 (± 2.29), treatment B = 44.29 (± 3.39),
treatment C = 48.96 (± 3.75), treatment D = 50.12 (± 5.13). Control group A was statistically
distinct from experimental variables B (p<0.01), C (p<0.01) and D (p<0.01), however B, C & D
were not statistically significant from each other. Addition of a low or high-dose PAM in these
experiments did produce a noticeable increase in the survival of RGCs, and although not
statistically significant, resulted in a 14.9-23.3% increase in mean cell survival over agonist
alone.

Figure 4. Images obtained from similar locations on Plates A, B, C & D of a single experiment.
Viable cells take up calcein dye and fluoresce under fluorescence microscopy with FITC
excitation filter (460-490). Images were analyzed with QCapture Pro Imaging system and cell
counts were obtained with Image-Pro software. A) cells were left untreated as a control, B) cells
were treated with 100 nM agonist, C) cells were treated with 100 nM agonist and 50 nM PAM,
and D) cells were treated with 100 nM agonist and 100 nM PAM.
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Condition 2 differed from Condition 1 in the dosages of agonist and PAM used. In
Condition 2, treatment C contained very low dose concentration of PAM with agonist and
treatment D contained PAM without any agonist. The least squares means for viable cells of
Condition 2 are as follows: treatment A = 35.10 (± 3.93), treatment B = 44.35 (± 5.07),
treatment C = 62.96 (± 15.44), treatment D = 36.01 (± 5.73). Control group A was statistically
distinct from experimental variables B (p<0.01) and C (p<0.01), but not from D (p=0.38). In
treatment group D with PAM without any agonist, cell survival was nearly equal to that of
control. A comparison of the results from Condition 1 and Condition 2 can be found in Figure 5.
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Average RGC Count % Change from Control:
Experimental Condition 1
Sample Size n=9

Percent Change

200%

152.0%
143.7%
128.8%

150%

A= Control
B= 100 nM Agonist

100%
100%
50%

C= 100 nM Agonist &
50 nM Modulator

0%

D= 100 nM Agonist &
100 nM Modulator
Treatment Group

Average RGC Count % Change from Control:
Experimental Condition 2
Sample Size n=6
172.4%

Percent Change

200%

A= Control

128.7%

150%

103.2%
B= 100 nM Agonist

100%
100%

C= 100 nM Agonist &
20 nM Modulator

50%

D= 100 nM Modulator
0%
Treatment Group

Figure 5. Summary of results obtained in Conditions 1 & 2. Cell counts for each treatment group
were compared to internal controls to obtain a percent change. Percent change values were
averaged to produce results displayed above. For Condition 1, treatment groups B, C, and D
produced a 28.8%, 43.7%, and 52.0% increase in cell survival, respectfully. For Condition 2,
treatment groups B, C, and D produced a 28.7%, 72.4%, and 3.2% increase in cell survival,
respectfully. Error bars represent standard error. Refer to Table 1 for a breakdown of
pharmacologic treatment groups.
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Enzyme Inhibitors Produce a Change in Cell Survival Response
Conditions 3, 4 & 5 were conducted to analyze and evaluate proposed mechanisms of
enzyme pathway involvement in RGC neuroprotection. In Condition 3 experiments, treatment
groups B, C & D received pre-treatment with LY 294002 to inhibit PI3 kinase. PI3 kinase is
proposed to play a role in the ACh neuroprotection pathway; therefore, the hypothesized
finding for this condition would be a decrease in neuroprotection and subsequently no survival
difference between control plates and pharmacotherapy plates. Statistical analysis of Condition
3 (n=4) revealed no significant difference in cell survival between control and treatment groups
B, C & D (p= 0.052, p=0.32, p=0.31, respectively). Least squares means for the treatment groups
were as follows: treatment A = 19.75 (± 5.26), treatment B = 24.56 (± 7.60), treatment C = 18.58
(± 5.62), treatment D = 20.90 (± 5.12). This result is graphically displayed in Figure 6.
Condition 4 was conducted under similar methods but utilized the compound SB 203580
to inhibit p38 MAP kinase. This enzyme plays a role in the glutamate pathway that is proposed
to participate in excitotoxicity and subsequent RGC death in a glaucomatous state. The
hypothesized finding through inhibition of p38 MAP kinase is a decrease in toxic insult and
subsequent increase in cell survival. Statistical analysis of Condition 4 (n=4) revealed control
group A was statistically distinct from experimental variables B (p<0.01), C (p<0.01) and D
(p<0.01), however B, C & D were not statistically significant from each other. Least squares
means for the treatment groups were as follows: treatment A = 23.19 (± 3.38), treatment B =
33.65 (± 9.15), treatment C = 29.29 (± 4.99), treatment D = 32.00 (± 6.08). The result is
graphically displayed in Figure 6.
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Finally, Condition 5 mirrored Conditions 3 & 4 but utilized the compound ABT 199 to
inhibit Bcl-2. Bcl-2 is a regulator protein involved in the suppression of apoptosis; it is proposed
to play a role in the ACh neuroprotection pathway targeted by PNU-282987. As such, inhibition
of Bcl-2 would result in suppression of neuroprotection on pharmacologically-treated plates
and similar cell survival between control and experimental variables. Statistical analysis of
Condition 5 (n=4) revealed no significant difference in cell survival between control and
treatment groups B, C & D (p= 0.27, p=0.39, p=0.37, respectively). Least squares means for the
treatment groups were as follows: treatment A = 50.00 (± 16.8), treatment B = 56 (± 17.75),
treatment C = 53.04 (± 16.97), treatment D = 53.63 (± 13.10). The result is graphically displayed
in Figure 6 alongside the results of Conditions 3 & 4.
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Average RGC Count % Change from Control:
Experimental Condition 3
Sample Size n=4
A= Control
Percent Change

200%
117.8%

150%

91.7%

100%

107.1%

100%

B= PI3 kinase inhibitor + 100
nM Agonist
C= PI3 kinase inhibitor + 100
nM Agonist & 50 nM
Modulator
D= PI3 kinase inhibitor + 100
nM Agonist & 100 nM
Modulator

50%
0%
Treatment Group

Average RGC Count % Change from Control:
Experimental Condition 4
Sample Size n=4
A= Control
Percent Change

200%

138.6%

136.6%
125.0%

150%
100%
100%

C= p38 MAP kinase inhibitor +
100 nM Agonist & 50 nM
Modulator
D= p38 MAP kinase inhibitor +
100 nM Agonist & 100 nM
Modulator

50%
0%

B= p38 MAP kinase inhibitor +
100nM Agonist

Treatment Group

Average RGC Count % Change from Control:
Experimental Condition 5
Sample Size n=4

Percent Change

200%
119.7% 123.2%

150%

A= Control

116.7%

100%

B= Bcl-2 inhibitor + 100 nM
Agonist

50%

C= Bcl-2 inhibitor + 100 nM
Agonist & 50 nM Modulator

100%

0%

D= Bcl-2 inhibitor + 100 nM
Agonist & 100 nM Modulator

Treatment Group

Figure 6. Comparison of RGC counts in enzyme inhibitor experiments. There was no statistically
significant difference among the treatment groups in Conditions 3 or 5. In Condition 4 the experimental
variables B, C, and D were all statistically significant from control. Error bars represent MSE.
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CHAPTER 5
CONCLUSION

Neuroprotection
This study was designed to test the neuroprotective properties of a specific nAChR
agonist, PNU-282987, in combination with a positive allosteric modulator, PNU-120596, in a cell
culture model of glaucoma. In previous studies using cultured porcine RGCs and in vivo rat
RGCs, ACh and nicotine have demonstrated neuroprotection through activation of the α7
nAChR (Wehrwein et al., 2004, Thompson et al. 2006, Iwamoto et al., 2013). The goal of this
study was to replicate these results and evaluate the additive effect of an allosteric modulator
that is specific for the α7 receptor. Treatment of cells with the α7 nAChR agonist prior to
incubation resulted in an increase in cell survival, as seen in previous experiments. This increase
was statistically significant. Addition of the PAM produced a dose-dependent increase in cell
survival over that of agonist alone, also statistically significant compared to control. The
combination of agonist and PAM was not statistically significant over agonist alone; however,
the trend of increased neuroprotection with dose-dependent PAM is evident in the data. PAM
in absence of agonist produced no change in cell survival, suggesting that the PAM works
allosterically as hypothesized. Much in the same way a benzodiazepine like Diazepam (Valium)
works to modulate the GABA receptor, PNU-120596 likely works to increase the effect of the
agonist rather than producing an additive neuroprotective effect of its own.
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As mentioned previously, there are many theories pertaining to the mechanism of cell
death associated with glaucoma. Previous studies in this lab have focused on a model of
excitotoxicity related to overstimulation of cellular receptors by the neurotransmitter,
glutamate. In this study no additional insult (i.e. excess glutamate) was employed. Prior to
retinal dissociation and culture, the axons of all retinal RGCs were severed via cut of the optic
nerve. RGCs die off in a gradual, predictable pattern in this model as described by Wehrwien et
al. in 2004. In this study, agonist and PAM provided neuroprotection for RGCs in the absence of
a specific insult, suggesting their use is not limited to an excitotoxic model. While release of
excess glutamate from injured cells may still be the insult producing cell death, it is possible
that another proposed mechanism is responsible for RGC death (i.e. oxidative stress,
autoimmune regulation, glial cell activation, endoplasmic reticulum stress, endothelin receptor
activation, neurotrophic factor deprivation, or hypoperfusion of the optic nerve). Treatment
with α7 nAChR agonist and PAM provide neuroprotection for RGCs in a model of nonspecific
cellular injury which suggests their usefulness as a neuroprotective agent may extend to injured
neurons regardless of mechanism of injury.
Mechanism of Action
A previous study by Asomugha et al. utilized ELISA techniques to evaluate the enzymatic
pathways utilized by the α7 nAChR. This previous study revealed that ACh neuroprotection is
mediated through stimulation of the PI3 kinase

Akt

Bcl-2 pathway as well as

inhibition of the p38 MAP kinase pathway. Conversely, glutamate excitotoxicity is mediated
through stimulation of the p38 MAP kinase signaling pathway. To evaluate the additive effect of
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a PAM on this model, specific enzyme inhibitors for PI3 kinase, p38 MAP kinase, and the final
protein target of both pathways, Bcl-2, were added to cell culture prior to incubation. When PI3
kinase was blocked in this study, the cell survival of RGCs in agonist and agonist + PAM groups
was similar to that of control. The neuroprotective effect of agonist and PAM was completely
eliminated in the absence of PI3 kinase. This finding suggests that neuroprotection by the
combination of agonist and PAM is mediated through PI3 kinase, as is agonist alone.
Although glutamate was not specifically added to culture to evaluate its role in cell
death through excitotoxicity, an inhibitor for the hypothesized cell death pathway was tested.
P38 MAP kinase plays a role in cell death through down-regulation of Bcl-2, or antagonistic
effect of the PI3 kinase pathway (Asomugha et al. 2010). When p38 MAP kinase was blocked,
RGC cell survival in agonist and agonist + PAM groups was significantly increased as compared
to control, however not to the level of survival seen in its presence. This result raises questions
about the interaction between the p38 MAP kinase death pathway and the PI3 kinase survival
pathway. Does the PI3 kinase pathway require some input from p38 MAP kinase to substantiate
its neuroprotective properties? Or, is the action of the p38 MAP kinase pathway different in the
absence of an added glutamate insult? It is also possible that blocking cell death is different
from increasing cell survival, and thus a significant increase in cell survival is not to be expected.
That is, the p38 MAP kinase cell death pathway may play a direct role in decreased numbers of
RGCs in vitro, but does not have a direct effect on the increased number of RGCs in the
presence of agonist and PAM.
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Finally, an inhibitor for Bcl-2 was used to analyze its role in cell survival. Bcl-2 is an antiapoptotic protein that is up-regulated by PI3 kinase and down-regulated by p38 MAP kinase. It
is hypothesized to be the final target of the ACh neuroprotective pathway as well as the p38
MAP kinase death pathway. In its absence one would expect a total loss of neuroprotection and
RGC survival with agonist + PAM to be equal to that of control. Interestingly, RGC survival in
absence of Bcl-2 was increased with agonist + PAM as compared to control. The amplitude of
this increase was less than that in the presence of Bcl-2 from previous experiments. This result
would need to be strengthened for statistical significance with a greater experimental value
than achieved in this study (n=4). However, the data trend in this study suggests that while
some of the increase in RGC survival is mediated through the PI3 kinase

Akt

Bcl-2

pathway, another pathway may be contributing to cell survival. That is, if the Bcl-2 pathway
was really the essential end target then blocking it should drop the increase in survival to zero,
as seen in PI3 kinase inhibition. The persistent increased survival is suggestive of an additional
mechanism for survival. This additional pathway must be activated downstream of PI3 kinase as
its absence resulted in total blockade of neuroprotection, and upstream of Bcl-2 as its absence
resulted in cell survival at a lesser incidence.
Each of the aforementioned enzyme inhibitor experiments utilized a known inhibitory
compound for targeted enzymes in the hypothesized signaling cascade of PNU-282987 and
PNU-120596. Each of the inhibitory reagents utilized in this study are widely produced and used
with proven efficacy for their target function. The inhibitor reagents were applied at a
consistent concentration of 10 nM thirty minutes prior to drug application on experimental
plates B, C & D. Cell survival on these plates was then compared to control plate A which
54

contained no inhibitor or pharmacotherapy. It is warranted to repeat these methods with an
additional variable of inhibitor alone. Inhibitor in the absence of pharmacotherapy is a justified
variable because it would allow for observation of cell survival in the absence of enzymes of
interest but without the influence of pharmacotherapy. This would help to further clarify the
role of PNU-282987 and PNU-120596 in the activation of Bcl-2 as a final target protein. It would
also further clarify what, if any, role p38 MAP kinase plays in activation of apoptotic RGC death
to determine if this pathway has a direct or indirect role in the neuroprotection provided by the
α7 nAChR agonist and PAM. Continuation of this enzyme inhibitor experimentation will be
conducted in this laboratory in the near future to augment the data obtained in this study.
Implications
The results of this study suggest that a PAM can be used in combination with an α7
nAChR agonist, PNU-282987, to enhance its effect as a neuroprotective agent. The PAM has no
neuroprotective effect on its own, but rather works allosterically to enhance the effect of the
agonist. This neuroprotective effect was assessed on an in vitro model of porcine RGCs that
were subject to axotomy. The absence of a specific cellular injury model suggests that the
protection provided by these agents may be applicable in a number of different models, as well
as an in vivo model of nonspecific neurodegeneration. It has been proposed that increased IOP
presses against RGC axons as they make a 90° turn at the optic nerve head to exit the eye,
damaging RGCs and contributing to neurodegeneration. This is referred to as the “Achilles heel”
of the anatomy of the retina (Dreyer et al., 1996). If this natural mechanism of injury leads to
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RGC injury in absence of a specific insult, pharmacotherapy with an α7 nAChR agonist and PAM
would be effective form of neuroprotection.
The role of glutamate excitotoxicity remains yet controversial, and further experiments
with measured levels of glutamate would be needed to determine if glutamate plays a role in
this nonspecific model of injury. Enzyme inhibitor experiments propose that the combination of
agonist and PAM work via the PI3 kinase

Akt

Bcl-2 pathway to up-regulate Bcl-2,

which has known anti-apoptotic properties. This cell survival pathway via PI3 kinase has been
linked to calcium influx through activated α7 nAChRs (Brandt et al. 2010). Results of this study
also suggest that an additional pathway may be contributing to enhanced cell survival, and this
pathway occurs somewhere between PI3 kinase and Bcl-2. Further research is needed to
identify this additional pathway. Once identified, inhibition of this pathway in combination with
inhibition of Bcl-2 should produce a complete loss of neuroprotection under these culture
conditions to confirm its validity.
Limitations and Potential Applications
This study was limited to findings of an in vitro culture model of glaucoma utilizing
isolated porcine RGCs. The question remains, does a combination of PNU-282987 and PAM
provide neuroprotection for RGCs in an in vivo model of glaucoma? Would the PAM continue to
work allosterically to enhance the effect mediated by nAChRs under physiologic conditions in
vivo? Previous studies in this laboratory have demonstrated that PNU-282987 inhibits the loss
of RGCs in glaucoma-like conditions in a dose-dependent manner in both in vitro and in vivo
studies through activation of α7 nAChRs (Linn et al. 2011, Iwamoto et al. 2013). Acetylcholine
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and nicotine provide neuroprotection through this same mechanism within the retina
(Wehrwein et al. 2004, Thompson et al. 2006, Asomugha et al. 2010). In this study the PAM was
tested only with the specific agonist PNU-282987, but it is possible that it would also enhance
the effect of naturally-occurring ACh. In the retina, ACh is released from starburst amacrine
cells, which synapse onto RGCs (Masland, 1988). The effect of a PAM in combination with
naturally-occurring ACh was not able to be evaluated in this study because RGCs were isolated
and cultured in the absence of starburst amacrine cells. If the PAM used in this study could
allosterically enhance the effect of ACh as it does for PNU-282987, it could potentially be used
to substantiate the body’s natural protective response against RGC stress. If not in combination
with ACh, the potential still remains for PNU-282987 and PAM to be used as a
pharmacotherapeutic strategy for patients with neurodegenerative diseases of the retina, such
as glaucoma.
There is also a potential for application of these agents for neuroprotection against
neurodegenerative diseases elsewhere in the nervous system, such as Alzheimer’s disease.
Alzheimer’s disease is characterized by neurodegeneration resulting from apoptosis of neurons
and formation of neurotoxic amyloid plaques in the brain (Nikura et al., 2006). Previous
epidemiologic studies identified a decreased incidence of Alzheimer’s disease in nicotine users,
and thus a neuroprotective effect of nicotine with regards to formation of amyloid plaques
(Fratiglioni and Wang, 2000). Nicotine affords this effect through a mechanism mediated by α7
nAChRs, demonstrated by Hellstrom-Lindahl et al. (2004) through inhibition studies with an α7
nAChR antagonist, Mecamylamine, to block nicotine’s effect in transgenic mice containing
Alzheimer’s disease. In the absence of the α7 nAChR, nicotine did not have a neuroprotective
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effect. Therefore, the α7 nAChR is involved in neuroprotection of diseases in the retina and
elsewhere in the nervous system, providing opportunity for future application of an α7 nAChR
agonist and α7 specific PAM in other neurodegenerative disease states.
Conclusion
The findings of this study are suggestive of future application of an α7 nAChR agonist in
combination with a PAM for protection of RGCs in the setting of glaucoma, and possibly in
other neurodegenerative diseases as well. Previous studies have demonstrated success with
PNU-282987 as a neuroprotective strategy for RGCs in an in vivo rat model of glaucoma
(Iwamoto et al. 2014). This study’s in vitro finding suggests that a PAM could enhance the
neuroprotection provided by PNU-282987. An in vivo approach to the repetition of this study
would further elucidate the role of a PAM in the protection of RGCs both in combination with a
specific α7 nAChR agonist and in combination with naturally-occurring ACh in a physiologic
setting. This study has implicated the PI3 kinase

Bcl-2 pathway in the action of α7 nAChR

neuroprotection, and also suggested the utilization of an additional unidentified pathway
downstream from PI3 kinase. Further insight into any additional pathway utilized by these
agents is also warranted in future research. Use of these agents could ultimately lead to
therapeutic prevention of glaucoma and potentially other neurodegenerative diseases.
As members of the healthcare team it is important to not only provide the highest level
of care, but also to continue research to advance the highest level of care. Glaucoma, a chronic
and debilitating disease that is responsible for current visual impairment in over 6 million
people worldwide, remains without a cure. To date, all treatment strategies for glaucoma are
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designed to decrease IOP within the anterior chamber of the eye (The Ophthalmic News &
Education Network, 2010). Elevated IOP remains the only risk factor currently recognized by the
FDA despite the fact that not all cases of glaucoma present with IOP, and studies have shown
lowering IOP does not ensure prevention of RGC death (Sena et al., 2010). Previous studies in
this lab have shown that treatment with the α7 nAChR agonist, PNU-282987, in eye drop form
after the onset of glaucomatous conditions inhibits the loss of RGCs in vivo (Iwamoto et al.,
2014). Results from this study demonstrate an enhanced level of PNU-282987 neuroprotection
with the addition of a PAM, and possible application of a PAM to enhance the physiologic
response to neurodegenerative insult. Clinically, these results prompt further research into a
novel therapeutic approach to glaucoma that is not targeted at altering IOP. It also warrants
further research into the clinical effectiveness of a PAM on the physiologic neuroprotective
response of ACh and the α7 nAChR. The results from this study prompt further research that
could dramatically change the treatment approach for patients with glaucoma by targeting the
disease at the level of the retina where irreversible damage and vision loss ultimately occurs.
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